Physician profile
Andrew G Ayars
NPI 1336286608
$1,717.77
in general payments reported to CMS, 2019-2025
21 companies · $718 in 2025
The $718 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $11.44 · 2023: $313 · 2024: $569 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Consulting Fee: $78.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.17 |
| Consulting Fee | $78.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $177.09 | 2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $173.06 | 2019-2025 | |
| Genzyme Corporation | $170.95 | 2023-2024 | |
| Blueprint Medicines Corporation | $168.80 | 2023-2025 | Ayvakit |
| Csl Behring | $141.64 | 2019-2025 | Hizentra, Andembry |
| Pharming Healthcare, INC. | $132.29 | 2024-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $128.49 | 2023-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $118.31 | 2023-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $79.50 | 2023-2024 | Eohilia, Hyqvia |
| Adma Biomanufacturing LLC | $78.72 | 2024-2025 | |
| Amgen INC. | $78.71 | 2024-2025 | Actimmune, Tezspire |
| Grifols USA, LLC | $45.84 | 2024-2025 | Gamunex-C, Xembify |
| Genentech USA, INC. | $41.74 | 2023-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $29.89 | 2024 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $27.70 | 2025 | Neffy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $24.96 | 2023 | Auvi-Q |
| Cycle Pharmaceuticals INC | $21.72 | 2025 | Sajazir |
| Octapharma USA, INC. | $21.64 | 2024 | Octagam Immune Globulin (Human) |
| Merck Sharp & Dohme LLC | $21.30 | 2023 | |
| Ionis Pharmaceuticals, INC. | $19.87 | 2025 | Dawnzera |
| Shire North American Group INC | $15.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ayars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.